Literature DB >> 19390942

Chemo-hyperthermic peritoneal perfusion (CHPP) for appendiceal pseudomyxoma peritonei.

Kanji Katayama1, Akio Yamaguchi, Makoto Murakami, Kenji Koneri, Hideki Nagano, Kei Honda, Yasuo Hirono, Takanori Goi, Atsushi Iida, Hiroshi Ito.   

Abstract

BACKGROUND: Pseudomyxoma peritonei is derived mostly from the rupture of an appendiceal cystic tumor and produces a large quantity of mucinous substance. Though its malignancy level is low, radical resection is difficult and its prognosis is poor. In some institutes in European countries and the United States, multidisciplinary treatment with chemo-hyperthermia at a relatively low temperature is performed following subtotal peritonectomy. We carried out high-temperature chemo-hyperthermic peritoneal perfusion following incomplete resections of mucinous tumors in six patients.
METHODS: After resection of the main tumor and macroscopic gross tumor resection of dissemination, heated perfusate containing anticancer agents was poured into the peritoneal cavity and stirred and pumped into a circulation between the abdomen and a reservoir. The temperature of the surface of the peritoneum was maintained at around 43 degrees C.
RESULTS: The intraperitoneal space was sufficiently heated without severe complications. The pathological diagnosis in four of the patients was peritoneal mucinous carcinomatosis, and in the other two patients, it was intermediate type between peritoneal mucinous carcinomatosis and disseminated peritoneal adenomucinosis. Two patients died, 15 and 26 months after the treatment. The other four patients have survived for 4, 24, 26, and 80 months now, and two of them, who have survived for 26 and 80 months, received a second treatment 18 and 32 months, respectively, after the initial treatment. These results seemed not to be inferior to those in the reports from institutes in Europe and the United States which performed subtotal peritonectomy and then used mild hyperthermia in chemo-hyperthermia.
CONCLUSION: For treating pseudomyxoma peritonei, high-temperature chemo-hyperthermic peritoneal perfusion following incomplete tumor resection is effective even without peritonectomy.

Entities:  

Mesh:

Year:  2009        PMID: 19390942     DOI: 10.1007/s10147-008-0803-1

Source DB:  PubMed          Journal:  Int J Clin Oncol        ISSN: 1341-9625            Impact factor:   3.402


  8 in total

1.  Appendiceal mucocoeles and pseudomyxoma peritonei.

Authors:  Anupam Dixit; John H P Robertson; Satvinder S Mudan; Charles Akle
Journal:  World J Gastroenterol       Date:  2007-04-28       Impact factor: 5.742

Review 2.  Peritoneal surface oncology: review of a personal experience with colorectal and appendiceal malignancy.

Authors:  P H Sugarbaker
Journal:  Tech Coloproctol       Date:  2005-07-08       Impact factor: 3.781

3.  Survival analysis of pseudomyxoma peritonei patients treated by cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.

Authors:  Robert M Smeenk; Vic J Verwaal; Ninja Antonini; Frans A N Zoetmulder
Journal:  Ann Surg       Date:  2007-01       Impact factor: 12.969

4.  Long-term survival following treatment of pseudomyxoma peritonei: an analysis of surgical therapy.

Authors:  Thomas J Miner; Jinru Shia; David P Jaques; David S Klimstra; Murray F Brennan; Daniel G Coit
Journal:  Ann Surg       Date:  2005-02       Impact factor: 12.969

5.  Thermal dose determination in cancer therapy.

Authors:  S A Sapareto; W C Dewey
Journal:  Int J Radiat Oncol Biol Phys       Date:  1984-06       Impact factor: 7.038

6.  Cytoreductive surgery and peri-operative intraperitoneal chemotherapy as a curative approach to pseudomyxoma peritonei syndrome.

Authors:  P H Sugarbaker
Journal:  Eur J Surg Oncol       Date:  2001-04       Impact factor: 4.424

7.  Surgery combined with peritonectomy procedures and intraperitoneal chemohyperthermia in abdominal cancers with peritoneal carcinomatosis: a phase II study.

Authors:  O Glehen; F Mithieux; D Osinsky; A C Beaujard; G Freyer; Ph Guertsch; Y Francois; P Peyrat; G Panteix; J Vignal; F N Gilly
Journal:  J Clin Oncol       Date:  2003-03-01       Impact factor: 44.544

8.  Disseminated peritoneal adenomucinosis and peritoneal mucinous carcinomatosis. A clinicopathologic analysis of 109 cases with emphasis on distinguishing pathologic features, site of origin, prognosis, and relationship to "pseudomyxoma peritonei".

Authors:  B M Ronnett; C M Zahn; R J Kurman; M E Kass; P H Sugarbaker; B M Shmookler
Journal:  Am J Surg Pathol       Date:  1995-12       Impact factor: 6.394

  8 in total
  3 in total

Review 1.  Pseudomyxoma peritonei as an intractable disease and its preoperative assessment to help improve prognosis after surgery: A review of the literature.

Authors:  Yuesi Zhong; Meihai Deng; Ruiyun Xu; Norihiro Kokudo; Wei Tang
Journal:  Intractable Rare Dis Res       Date:  2012-08

2.  Cytoreductive surgery with intraperitoneal chemotherapy to treat pseudomyxoma peritonei at nonspecialized hospitals.

Authors:  Toshiyuki Kitai; Masahiro Kawashima; Kenya Yamanaka; Kunio Ichijima; Hideaki Fujii; Susumu Mashima; Yasuyuki Shimahara
Journal:  Surg Today       Date:  2011-08-26       Impact factor: 2.549

3.  MUC2 protein expression status is useful in assessing the effects of hyperthermic intraperitoneal chemotherapy for peritoneal dissemination of colon cancer.

Authors:  Yuka Fujishima; Takanori Goi; Youhei Kimura; Yasuo Hirono; Kanji Katayama; Akio Yamaguchi
Journal:  Int J Oncol       Date:  2012-01-16       Impact factor: 5.650

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.